We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ReiThera Srl today announces the preliminary safety and immunogenicity data from the Phase 2 clinical "COVITAR" trial with GRAd-COV2, its novel COVID-19 vaccine candidate.
ReiThera has announced the first healthy volunteer has been dosed in a Phase 1 study of the Company's vaccine candidate (GRAd-COV2) against the novel coronavirus (SARS-CoV-2).